"New York Oncology Hematology (NYOH) is the leading provider of community-based cancer care and blood disorder services. With six convenient locations in Albany, Amsterdam, Clifton Park in Saratoga County, Hudson, and Troy, our team of 35 physicians and more than 350 cancer care specialists see more than 100,000 cancer visits a year."

During the past decade, New York Oncology Hematology PC - Clifton Park conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 13 clinical trials were completed, i.e. on average, 162.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Oncology Hematology PC - Clifton Park" #1 sponsor was "National Cancer Institute (NCI)" with 9 trials, followed by "Pfizer" with 2 trials sponsored, "AVEO Pharmaceuticals, Inc." with 1 trials sponsored, "Calithera Biosciences, Inc" with 1 trials sponsored and "GOG Foundation" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Oncology Hematology PC - Clifton Park" #1 collaborator was "Cancer and Leukemia Group B" with 4 trials as a collaborator, "NCIC Clinical Trials Group" with 3 trials as a collaborator, "North Central Cancer Treatment Group" with 3 trials as a collaborator, "SWOG Cancer Research Network" with 3 trials as a collaborator and "NRG Oncology" with 2 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "New York Oncology Hematology PC - Clifton Park" are "Breast Adenocarcinoma" (2 trials), "Stage IA Breast Cancer AJCC v7" (2 trials), "Stage IB Breast Cancer AJCC v7" (2 trials), "Stage IIA Breast Cancer AJCC v6 and v7" (2 trials) and "Stage IIB Breast Cancer AJCC v6 and v7" (2 trials). Many other conditions were trialed in "New York Oncology Hematology PC - Clifton Park" in a lesser frequency.

Most popular intervention types in "New York Oncology Hematology PC - Clifton Park" are "Drug" (16 trials), "Biological" (9 trials), "Other" (9 trials), "Radiation" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (8 trials), "Quality-of-Life Assessment" (6 trials), "Bevacizumab" (3 trials), "Cisplatin" (3 trials) and "Doxorubicin Hydrochloride" (3 trials). Other intervention names were less common.

The vast majority of trials in "New York Oncology Hematology PC - Clifton Park" are 15 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "New York Oncology Hematology PC - Clifton Park". undefined are not yet recruiting, 2 are recruiting, 8 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 7 completed trials in New York Oncology Hematology PC - Clifton Park, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in New York Oncology Hematology PC - Clifton Park, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".